GSK plc / CureVac N.V.

Respiratory infectious diseases (seasonal influenza, COVID-19, avian/pandemic influenza)

180M US cases/yr · $20.0B Global seasonal respiratory vaccine market (flu + COVID-19, 2024) · $12.5B Moderna Spikevax 2022 peak COVID vaccine sales (mRNA benchmark)

Disease Overview

The US seasonal influenza vaccine market is driven by universal recommendation for annual vaccination of all persons ≥6 months by CDC/ACIP. The CDC estimates 9-41 million annual US flu cases, 140,000-710,000 hospitalizations, and 12,000-52,000 deaths depending on season. Approximately 170-180 million Americans receive seasonal flu vaccines annually, generating roughly $2.5-3B in US flu vaccine revenue (Sanofi's Fluzone/Flublok, GSK's Fluarix/Flulaval, Seqirus's Fluad/Flucelvax, AstraZeneca's FluMist). The COVID-19 vaccine market post-pandemic has normalized at an estimated $10-15B globally with seasonal booster uptake, dominated by Pfizer/BioNTech's Comirnaty and Moderna's Spikevax mRNA platforms and Novavax's protein-subunit Nuvaxovid. Avian/pandemic influenza (notably H5N1) remains a priority biosecurity concern; BARDA and international health authorities have stockpiled 4.8M+ doses of pre-pandemic H5N1 vaccines (CSL Seqirus, Sanofi, GSK ID Biomedical) and signed 2024 contracts totaling ~$500M for additional capacity. mRNA platforms offer speed advantages critical to pandemic response. The combined addressable global respiratory vaccine market exceeds $20 billion annually. Flu mRNA has been tested against egg-based and recombinant comparators with mixed Phase 3 readouts to date — Moderna mRNA-1010 underperformed B/Yamagata-containing comparator in 2023, and BioNTech's qIRV has shown variable immunogenicity.

Competitive Landscape

The mRNA vaccine space is a two-horse leader board in active products — Pfizer/BioNTech's Comirnaty (tozinameran) and Moderna's Spikevax (elasomeran) — with Moderna pursuing flu (mRNA-1010, mRNA-1083 flu+COVID combo), RSV (mRNA-1345 approved as mRESVIA May 2024), and CMV vaccines, and Pfizer/BioNTech pursuing quadrivalent influenza (qIRV) and combo flu+COVID programs. Sanofi/Translate Bio had an mRNA flu program but discontinued following disappointing Phase 1/2 data. GSK had exited direct mRNA development before re-engaging CureVac through this 2024 restructuring. The seasonal flu vaccine incumbents (Sanofi Fluzone/Flublok, GSK Fluarix, Seqirus Fluad/Flucelvax, AstraZeneca FluMist) rely on egg-based or recombinant protein platforms. For COVID-19, Pfizer's Comirnaty dominates with Moderna's Spikevax and Novavax's Nuvaxovid as distant second and third. GSK's $8.1B Arexvy (RSV) success demonstrates commercial upside in respiratory vaccines but does not leverage mRNA. The restructured CureVac deal consolidates mRNA IP and clinical assets under GSK, giving it a potential path back into mRNA-based seasonal flu and pandemic preparedness without the dilution of joint economics.